Bausch Health Companies Insider Trading
TSX: BHC
1
All Trades
1
Significant
0
Notable
0
Clusters
0
Repeat
| Company | Insider | Title | Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|
| Bausch Health Companies | Paulson, John | Director | 25-Nov-25 | 2,500,000 | $6.25USD | $15,625,000 | 2,500,000 | New | Significant |
Stock Chart
Related Companies to Explore
Company Info
Bausch Health Companies is a multinational pharmaceutical and medical device company headquartered in Laval, Quebec, Canada. The company develops, manufactures, and markets prescription drugs, over-the-counter medications, and medical devices across multiple therapeutic areas including dermatology, gastroenterology, neurology, and ophthalmology. Bausch Health operates through several key divisions: Bausch + Lomb for eye health products including contact lenses, surgical equipment, and pharmaceuticals; Salix Pharmaceuticals focusing on gastrointestinal treatments; Ortho Dermatologics for prescription dermatology products; and International Rx for global pharmaceutical operations. The company’s notable products include Xifaxan for irritable bowel syndrome, Jublia for toenail fungus, and various Bausch + Lomb eye care solutions. Bausch Health has manufacturing facilities and commercial operations in over 40 countries, with significant presence in North America, Europe, Asia-Pacific, and Latin America. The company was formerly known as Valeant Pharmaceuticals International and underwent significant restructuring following accounting scandals in the mid-2010s. Under new leadership, Bausch Health has focused on debt reduction, portfolio optimization, and rebuilding its reputation while maintaining its position as a major player in specialty pharmaceuticals and eye health products.